Senores Pharmaceuticals has approved the reallocation of ₹100.02 crore from its ₹500 crore IPO proceeds, subject to shareholder approval through a postal ballot. The proposal, recommended by the Audit Committee, aims to align capital allocation with evolving business priorities and expansion opportunities while ensuring transparent utilisation of IPO funds.